FDA 483 - Nationwide Laboratories, LLC - November 27, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Nationwide Laboratories, LLC, an own label distributor, was cited for significant deficiencies in its quality system and postmarketing adverse drug experience procedures. The firm lacks a functional quality control unit, a repeat observation from 2016, and fails to follow written procedures for quality oversight. Additionally, the company has inadequate written procedures for the surveillance, receipt, evaluation, and reporting of adverse drug experiences to the FDA.
ID · 029e9a57-884d-41cf-86c4-800d62c25ee5